|
1
|
Tsuji W, Teramukai S, Ueno M, Toi M and
Inamoto T: Prognostic factors for survival after first recurrence
in breast cancer: A retrospective analysis of 252 recurrent cases
at a single institution. Breast Cancer. 21:86–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giordano SH, Buzdar AU, Smith TL, Kau SW,
Yang Y and Hortobagyi GN: Is breast cancer survival improving?
Cancer. 100:44–52. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gennari A, Conte P, Rosso R, Orlandini C
and Bruzzi P: Survival of metastatic breast carcinoma patients over
a 20-year period: A retrospective analysis based on individual
patient data from six consecutive studies. Cancer. 104:1742–1750.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Greenberg PA, Hortobagyi GN, Smith TL,
Ziegler LD, Frye DK and Buzdar AU: Long-term follow-up of patients
with complete remission following combination chemotherapy for
metastatic breast cancer. J Clin Oncol. 14:2197–2205. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Falkson G, Gelman RS, Leone L and Falkson
CI: Survival of premenopausal women with metastatic breast cancer.
Long-term follow-up of eastern cooperative group and cancer and
leukemia group B studies. Cancer. 66:1621–1629. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rahman ZU, Frye DK, Smith TL, Asmar L,
Theriault RL, Buzdar AU and Hortobagyi GN: Results and long term
follow-up for 1581 patients with metastatic breast carcinoma
treated with standard dose doxorubicin-containing chemotherapy: A
reference. Cancer. 85:104–111. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Burstein HJ, Keshaviah A, Baron AD, Hart
RD, Lambert-Falls R, Marcom PK, Gelman R and Winer EP: Trastuzumab
plusvinorelbine or taxane chemotherapy for HER2-overexpressing
metastatic breast cancer: The trastuzumab and vinorelbine or taxane
study. Cancer. 110:965–972. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baselga J, Cortés J, Kim SB, Im SA, Hegg
R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al:
Pertuzumab plus trastumab plus docetaxel for metastatic breast
cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Verma S, Miles D, Gianni L, Krop IE,
Welslau M, Baselga M, Pegram M, Oh DY, Diéras V, Guardino E, et al:
Trastuzumab emtansine for HER2-positive advanced breast cancer. N
Engl J Med. 367:1783–1791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Prineri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International tils working group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hida AI and Ohi Y: Evaluation of
tumor-infiltrating lymphocytes in breast cancer; proposal of a
simpler method. Ann Oncol. 26:23512015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jia W, Wu J, Jia H, Yang Y, Zhang X, Chen
K and Su F: The peripheral blood neutrophl-to-lymphocyte ratio is
superior to the lymphocyte-to-monocyte ratio for predicting the
long-term survival of triple-negative breast cancer patients. PLoS
One. 10:e01430612015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Orditura M, Galizia G, Diana A, Saccone C,
Cobellis L, Ventriglia J, Iovino F, Romano C, Morgillo F, Mosca L,
et al: Neutrophil to lymphocyte ratio (NLR) for prediction of
distant metastasis-free survival (DMFS) in early breast cancer: A
propensity score-matched analysis. ESMO Open. 1:e0000382016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iwase T, Sangai T, Sakakibra M, Sakakibra
J, Ishigami E, Hayama S, Nakagawa A, Masuda T, Tabe S and Nagashima
T: An increased neutrophil-to-lymphocyte ratio predicts poorer
survival following recurrence for patients with breast cancer. Mol
Clin Oncol. 6:266–270. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ethier JL, Desautels D, Templeton A, Shah
PS and Amir E: Prognostic role of neutrophil-to-lymphocyte ratio in
breast cancer. A systematic review and meta-analysis. Breast Cancer
Res. 19:22017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guthrie GJ, Charles KA, Roxburgh CS,
Horgan PG, McMillan DC and Clarke SJ: The systemic
inflammation-based neutrophil-lymphocyte ratio: Experience in
patients with cancer. Crit Rev Oncol Hematol. 88:218–230. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Acharyya S and Massague J: Arresting
supporters: Targeting neutrophils in metastasis. Cell Res.
26:273–274. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bird L: Tumour immunology: Neutrophils
help tumours spread. Nat Rev Immunol. 16:74–75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wculek SK and Malanchi I: Neutrophils
support lung colonization of metastasis-initiating breast cancer
cells. Nature. 528:413–417. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dieci MV, Mathieu MC, Guarneri V, Conte P,
Delaloge S, Andre F and Goubar A: Prognostic and predictive value
of tumor-infiltrating lymphocytes in two phase III randomized
adjuvant breast cancer trials. Ann Oncol. 26:1698–1704. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Castaneda CA, Mittendorf E, Casavilca S,
Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C,
Dolores-Cerna K, et al: Tumor infiltrating lymphocytes in triple
negative breast cancer receiving neoadjuvant chemotherapy. World J
Clin Oncol. 7:387–394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hida AI, Sagara Y, Yotsumoto D, Kaemitsu
S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y and Ohi Y:
Prognostic and predictive impacts of tumor-infiltrating lymphocytes
differ between Triple-negative and HER2-positive breast cancers
treated with standard systemic therapies. Breast Cancer Res Treat.
158:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lambert AW, Pattabiraman DR and Weinberg
RA: Emerging biological principles of metastasis. Cell.
168:670–691. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Robinson DR, Wu YM, Vats P, Su F, Lonigro
RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, et al:
Activating ESR1 mutations in hormone-resistant metastatic breast
cancer. Nat Genet. 45:1446–1451. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zardavas D, Phillips WA and Loi S: PIK3CA
mutations in breast cancer: Reconciling findings from preclinical
and clinical data. Breast Cancer Res. 16:2012014. View Article : Google Scholar : PubMed/NCBI
|
